Use of cenobamate for the treatment of focal epilepsy: an Italian expert opinion paper

Author:

Villani Flavio1,Cianci Vittoria2,Di Bonaventura Carlo3,Di Gennaro Giancarlo4,Galimberti Carlo Andrea5,Guerrini Renzo6ORCID,La Neve Angela7,Mecarelli Oriano8,Pietrafusa Nicola9,Specchio Nicola9,Vigevano Federico9,Perucca Emilio10

Affiliation:

1. Division of Clinical Neurophysiology and Epilepsy Center, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

2. Regional Epilepsy Centre, Great Metropolitan Hospital, Bianchi-Melacrino Morelli, Reggio, Italy

3. Epilepsy Centre, Department of Human Neurosciences, “Sapienza” University of Rome, Rome, Italy

4. NEUROMED, IRCCS, Pozzilli, Isernia, Italy

5. Epilepsy Center, Mondino Foundation, IRCCS, Pavia, Italy

6. Neuroscience Department, Children’s Hospital A. Meyer-University of Florence, Italy

7. Department of Basic Medical Sciences, Neurosciences and Sense Organs, University Hospital of Bari “A. Moro”, Bari, Italy

8. Department of Human Neurosciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy

9. Department of Neuroscience, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy

10. Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy, Department of Medicine (Austin Health), University of Melbourne, and Department of Neuroscience, Monash University, Melbourne, Australia

Funder

organization of the expert meeting and the preparation of this manuscript were supported by an unconditional grant from Angelini Pharma

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Neurology (clinical),General Neuroscience

Reference26 articles.

1. 30 years of second-generation antiseizure medications: impact and future perspectives

2. Xcopri. Prescribing information. cited Nov 16, 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

3. European Medicine Agency Cenobamate authorization [cited 2021 Dec 22]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/ontozry

4. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial

5. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3